Document is current
Any future updates will be listed below
-
Authors
Mondal, Kallolika
Ghanty, Rituparna
Mahadevan, Anita
Waghmare, Girish
Santhoshkumar, Rashmi
BN, Nandeesh
Datta, Indrani https://orcid.org/0000-0001-8864-473X
-
Funding
Funding for this research was provided by:
Indian Council of Medical Research (2019-2697/SCR/ADHOC-BMS)
Department of Science and Technology, Ministry of Science and Technology, India (TDP DST/TDT/TDP-68/2022)
- License Information
-
More Information
Article History
Received: 12 January 2025
Accepted: 15 August 2025
First Online: 16 October 2025
Declarations
:
: For the animal experiments ethics approval was taken from the Institutional Animal Ethics Committee (IAEC) of NIMHANS, Bengaluru, India for the project title “Cell-free therapeutic approach to Parkinson’s disease using exosomes of human dental pulp stem cells as drug delivery tool through intranasal route in in vivo PD model targeting efficacy and bio-distribution” of approval number AEC/69/446/BP dated May 10, 2019 and Institutional Bio-safety Committee (IBSC) of approval number NIMHANS/DO/IBSC MEETING/2018 dated April 18, 2018. Approval for use of commercially available human dental pulp stem cells was obtained from Institutional Committee for Stem Cell and Research (IC-SCR) for the same project title on May 27, 2019 of approval number SEC/03/018/BP. For the commercially procured DPSCs, the original source (HiMedia Laboratories) has confirmed that all procedures related to this product have been reviewed and approved by IEC and IC-SCR at HiMedia Laboratories Private Limited and the donors had signed informed consent.
: The authors declare that they have no competing interests.
: The authors declare that they have not use AI-generated work in this manuscript.
